Session

The post TKI era

Poster Session 60

  • Location:
    Room Milan (Hall B2, level 0)
  • Chairs:
     J.P. Bedke, Tübingen (DE)
     M. Fujisawa, Kobe (JP)
     S. Oudard, Paris (FR)
  • Aims and objectives of this session

    This session will focus on new management options for renal cell cancer in the post-TKI era.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
763
Clinical impact of the dose modification of second-line targeted therapy for patients with metastatic renal cell carcinoma

By: Shirotake S.1, Yasumizu Y.1, Tanaka N.2, Mizuno R.2, Ito Y.2, Miyazaki Y.2, Masunaga A.3, Ito K.3, Hagiwara M.4, Asano T.3, Oya M.2, Oyama M.1

Institutes: 1Saitama International Medical Center, Dept. of Urology, Hidaka City, Saitama, Japan, 2Keio University School of Medicine, Dept. of Urology, Shinjuku, Tokyo, Japan, 3National Defense Medical College, Dept. of Urology, Tokorozawa, Saitama, Japan, 4Ichikawa General Hospital, Tokyo Dental College, Dept. of Urology, Ichikawa, Chiba, Japan

752
Prognostic significance of nephrectomy in patients with metastatic renal cell carcinoma treated with first-line systemic therapy: A 10-year retrospective analysis according to MSKCC and Heng risk criteria

By: Joung J.Y.1, Seo H.K.1, Kim S.H.1, Lee K.H.1, Chung J.1, Kwon W-A.2

Institutes: 1National Cancer Center, Dept. of Urology, center for Prostate Cancer, Goyang-Si,, South Korea, 2School of Medicine, Institute of Wonkwang Medical Science, Wonkwang University Sanbon Hospital, Dept. of Urology, Gunpo, Gyeonggi-Do, South Korea

* 753
Dynamic contrast-enhanced CT predicts response to antiangiogenic treatment in patients with metastatic renal cell cancer: Early results

By: Staehler M.1, Sterzik A.2, Casuscelli J.1, Karpitschka M.2, Roosen A.1, Szabados B.1, Spek A.1, Ziegelmüller B.1, Stief C.1, Reiser M.2, Graser A.2

Institutes: 1LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany, 2LMU-Klinikum der Universität München, Dept. of Radiology, Munich, Germany

754
Trends in cytoreductive nephrectomy in New South Wales, Australia

By: Beattie K.1, Patel M.I.1, Bang A.2, Smith D.P.2

Institutes: 1Westmead Hospital, Dept. of Urology, Sydney, Australia, 2Cancer Council, Cancer Research Division, Sydney, Australia

755
Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival

By: Meyer C.1, Trinh Q-D.1, Vetterlein M.1, Löppenberg B.1, Hanske J.1, Leow J.1, Sammon J.2, Abdollah F.2, Menon M.2, Kibel A.1, Chang S.1, Choueiri T.3, Sun M.1

Institutes: 1Brigham and Women’s Hospital, Dept. of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, 2Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America, 3Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America

756
Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell carcinoma patients treated with targeted therapies

By: Kröger N.1, Li H.2, De Velasco G.3, Donskov F.4, Sim H-W.5, Wells C.2, Stukalin I.2, Agarwal N.6, Parekh H.7, Rini B.7, Knox J.5, Pantuck A.8, Choueiri T.3, Heng D.2

Institutes: 1University Medicine Greifswald, Dept. of Urology, Greifswald, Germany, 2Tom Baker Cancer Center, Dept. of Medicine, Calgary, Canada, 3Dana Farber Cancer Institute, Dept. of Medicine, Boston, United States of America, 4Aarhus University Hospital, Dept. of Medicine, Aarhus, Denmark, 5Princess Margaret Cancer Centre, Dept. of Medicine, Toronto, Canada, 6University of Utah, Dept. of Medicine, Salt Lake City, United States of America, 7Cleveland Clinic, Dept. of Solid Tumor Oncology, Cleveland, United States of America, 8David Geffen School of Medicine, Dept. of Urology, Institute of Urologic Oncology, Los Angeles, United States of America

757
Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Final long-term results from EXIST-2

By: Bissler J.J.12, Radzikowska E.2, Zonnenberg B.3, Belousova E.4, Frost M.D.5, Sauter M.6, Kingswood J.C.7, Brakemeier S.8, De Vries P.J.9, Berkowitz N.10, Voi M.10, Peyrard S.11, Budde K.8, Franz D.N.1

Institutes: 1Cincinnati Children’s Hospital Medical Center, Dept. of Neurology, Cincinnati, United States of America, 2National Tuberculosis and Lung Diseases Research Institute, Dept. of Lung Disease, Warsaw, Poland, 3University Medical Center Utrecht, Dept. of Radiology and Nuclear Medicine, Utrecht, The Netherlands, 4Schlumberger Moscow Research Center, Moscow Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russia, 5Minnesota Epilepsy Group, Dept. of Epilepsy, Saint Paul, United States of America, 6Klinikverbund Kempten-Oberallgäu GGmbH, Facharzt F. Innere Medizin, Nephrologie, Infektiologie, Kempten, Germany, 7Royal Sussex County Hospital, The Trafford Dept of Renal Medicine, Brighton, United Kingdom, 8Charite-Universitatsmedizin, Berlin, Germany, 9University of Cape Town, Faculty of Health Sciences, Cape Town, South Africa, 10Novartis Pharma MCH, Dept. of Oncology, East Hanover, United States of America, 11Novartis Pharmaceuticals S.A.S, Dept. of Oncology, Rueil-Malmaison, France, 12University of Tennessee Health Science Center, St. Jude Children’s Research Hospital and Le Bonheur Children’s Hospital, Memphis, United States of America

759
Comprehensive analysis and validation of contemporary survival prognosticators in patients with metastatic renal cell carcinoma treated with targeted therapy

By: Koo K.C.1, Lee K.S.1, Lee D.H.2, Rha K.H.1, Hong S.J.1, Chung B.H.1

Institutes: 1Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, 2Busan National University College of Medicine, Dept. of Urology, Busan, South Korea

760
Alternative treatment with every other day dosing of sunitinib for patients with metastatic renal cell carcinoma: Efficacy and safety

By: Ohba K., Miyata Y., Asai A., Matsuo T., Sakai H.

Institutes: Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan

761
Prognostic significance of early CRP response for metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

By: Yasuda Y.1, Saito K.1, Kawamura N.1, Yuasa T.2, Yokoyama M.1, Matsuoka Y.1, Ishioka J.1, Numao N.1, Okuno T.3, Yamamoto S.2, Takahashi S.2, Yonese J.2, Fujii Y.1, Kihara K.4

Institutes: 1Tokyo Medical and Dental University, Dept. Of Urology, Tokyo, Japan, 2Cancer Institute Hospital, Dept. Of Urology, Tokyo, Japan, 3JA Toride Medical Center, Dept. Of Urology, Ibaraki, Japan, 4Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

762
Results of a phase I/II study in metastatic renal cell carcinoma patients treated with an adjuvant HLA personalized peptide vaccine after resection of metastases and comparison to a contemporary cohort of patients with mRCC

By: Bedke J.1, Rausch S.1, Gouttefangeas C.2, Kruck S.1, Walter K.1, Feyerabend S.1, Hennenlotter J.1, Laske K.2, Stevanovic S.2, Rammensee H-G.2, Stenzl A.1

Institutes: 1University of Tübingen, Dept. of Urology, Tübingen, Germany, 2University of Tübingen, Dept. of Immunology, Tübingen, Germany

Summary and context
 J.P. Bedke, Tübingen (DE)